Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single and multiple ascending dose study of M281 in healthy volunteers
NL-OMON43123Phase 1Active, not recruiting
- Sponsor
- Momenta Pharmaceuticals
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nipocalimab in autoimmune disease and Inflammatory Disorders (8 arms), sponsored by Momenta Pharmaceuticals. Primary endpoint: Safety and tolerability. Started May 2016; status: active, not recruiting.
02
Drugs
nipocalimab
03
Conditions
autoimmune diseaseInflammatory Disorders
Beyond the preview
Go deeper on NL-OMON43123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43123.